propan-2-yl (2S)-2-[[[(2R,3R,4R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: propan-2-yl (2S)-2-[[[(2R,3R,4R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
• 化学式: C₂₂H₂₉FN₃O₉P
• 分子量: 529.5
• InChiKey: TTZHDVOVKQGIBA-VKRUXWAVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  153
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• Nucleoside phosphoramidate prodrugs
  申请人：Gilead Pharmasset LLC

  公开号：EP2801580A1

  公开（公告）日：2014-11-12

  Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound or its stereoisomer, represented by the following structure: Also disclosed are uses and processes for preparing the compound represented by formula I.

  本文公开了用于治疗哺乳动物病毒感染的核苷衍生物磷酰胺原药，它是由以下结构表示的化合物或其立体异构体： 还公开了制备式 I 所表示的化合物的用途和工艺。
• HCV POLYMERASE INHIBITORS
  申请人：MEDIVIR AB

  公开号：EP3041855B1

  公开（公告）日：2017-07-26
• 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Verma Vishal A.

  公开号：US20140235567A1

  公开（公告）日：2014-08-21

  The present invention relates to 5′-Substituted Nucleoside Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, Z, R 1 , R 2 , R 3 and R 3′ are as defined herein. The present invention also relates to compositions comprising at least one 5′-Substituted Nucleoside Derivative, and methods of using the 5′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
• US9416154B2
  申请人：——

  公开号：US9416154B2

  公开（公告）日：2016-08-16
• [EN] IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS PERFECTIONNÉS DE PRÉPARATION DE SOFOSBUVIR ET D'INTERMÉDIAIRES DE CELUI-CI
  申请人：TEVA PHARMACEUTICALS INT GMBH

  公开号：WO2016196735A2

  公开（公告）日：2016-12-08

  The present disclosure provides new procedures and intermediates for the preparation of Sofosbuvir.